Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Atopic | 8 | 2019 | 86 | 3.750 |
Why?
|
| Dermatologic Agents | 4 | 2019 | 208 | 1.390 |
Why?
|
| Myoclonic Epilepsies, Progressive | 2 | 2018 | 2 | 1.340 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 2 | 2018 | 5 | 1.340 |
Why?
|
| Epidermis | 2 | 2018 | 23 | 1.330 |
Why?
|
| Scabies | 2 | 2017 | 2 | 1.230 |
Why?
|
| Syphilis, Congenital | 2 | 2017 | 3 | 1.070 |
Why?
|
| Eczema | 3 | 2019 | 12 | 0.890 |
Why?
|
| Biological Products | 4 | 2019 | 66 | 0.890 |
Why?
|
| Boron Compounds | 2 | 2019 | 8 | 0.860 |
Why?
|
| Lafora Disease | 2 | 2018 | 2 | 0.840 |
Why?
|
| Humans | 33 | 2019 | 29093 | 0.800 |
Why?
|
| Antiparasitic Agents | 2 | 2017 | 6 | 0.760 |
Why?
|
| Heart Transplantation | 1 | 2019 | 26 | 0.700 |
Why?
|
| Psoriasis | 2 | 2018 | 334 | 0.700 |
Why?
|
| Eosinophilia | 1 | 2019 | 16 | 0.680 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 196 | 0.680 |
Why?
|
| Drugs, Investigational | 1 | 2018 | 5 | 0.680 |
Why?
|
| Erythrocytes | 1 | 2018 | 43 | 0.660 |
Why?
|
| Dermatology | 2 | 2018 | 154 | 0.650 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 3 | 0.630 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 35 | 0.610 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2017 | 16 | 0.610 |
Why?
|
| Pruritus | 1 | 2017 | 58 | 0.600 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2016 | 8 | 0.590 |
Why?
|
| Referral and Consultation | 1 | 2016 | 113 | 0.540 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2015 | 5 | 0.530 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2015 | 12 | 0.520 |
Why?
|
| Administration, Cutaneous | 4 | 2019 | 107 | 0.490 |
Why?
|
| Dermatomyositis | 2 | 2016 | 19 | 0.470 |
Why?
|
| Administration, Oral | 3 | 2018 | 169 | 0.460 |
Why?
|
| Blister | 1 | 2012 | 7 | 0.450 |
Why?
|
| Extremities | 1 | 2012 | 48 | 0.440 |
Why?
|
| Livedo Reticularis | 1 | 2012 | 1 | 0.440 |
Why?
|
| Indans | 1 | 2012 | 25 | 0.430 |
Why?
|
| Leg | 1 | 2012 | 56 | 0.420 |
Why?
|
| Female | 14 | 2019 | 18164 | 0.400 |
Why?
|
| Pemphigus | 1 | 2010 | 8 | 0.380 |
Why?
|
| Diet | 2 | 2013 | 354 | 0.370 |
Why?
|
| Biopsy, Needle | 3 | 2019 | 89 | 0.370 |
Why?
|
| Child | 6 | 2019 | 2219 | 0.360 |
Why?
|
| Prognosis | 4 | 2018 | 1362 | 0.360 |
Why?
|
| Infant | 3 | 2017 | 969 | 0.360 |
Why?
|
| Infant, Newborn | 3 | 2017 | 598 | 0.350 |
Why?
|
| Adult | 8 | 2019 | 8420 | 0.350 |
Why?
|
| Algorithms | 1 | 2012 | 462 | 0.340 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 863 | 0.330 |
Why?
|
| Drug Utilization | 1 | 2008 | 47 | 0.330 |
Why?
|
| Male | 11 | 2019 | 17807 | 0.330 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 519 | 0.330 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 493 | 0.330 |
Why?
|
| Food, Formulated | 1 | 2008 | 10 | 0.320 |
Why?
|
| Adolescent | 5 | 2018 | 3254 | 0.320 |
Why?
|
| Retrospective Studies | 4 | 2018 | 3111 | 0.320 |
Why?
|
| Antipruritics | 2 | 2018 | 6 | 0.310 |
Why?
|
| Deglutition Disorders | 1 | 2008 | 50 | 0.310 |
Why?
|
| Permethrin | 2 | 2017 | 2 | 0.310 |
Why?
|
| Ivermectin | 2 | 2017 | 9 | 0.310 |
Why?
|
| Skin | 3 | 2018 | 203 | 0.300 |
Why?
|
| Risk Assessment | 4 | 2019 | 1305 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 285 | 0.280 |
Why?
|
| Hospitalization | 2 | 2018 | 417 | 0.250 |
Why?
|
| Quality of Life | 3 | 2019 | 816 | 0.230 |
Why?
|
| Middle Aged | 7 | 2018 | 10829 | 0.220 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 273 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2019 | 7 | 0.180 |
Why?
|
| Cellulitis | 1 | 2019 | 11 | 0.180 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 20 | 0.180 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2019 | 2 | 0.170 |
Why?
|
| Calciphylaxis | 1 | 2018 | 2 | 0.170 |
Why?
|
| Public Opinion | 1 | 2018 | 17 | 0.170 |
Why?
|
| Drug Design | 1 | 2018 | 44 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2019 | 48 | 0.170 |
Why?
|
| Pemphigoid Gestationis | 1 | 2018 | 2 | 0.170 |
Why?
|
| Sex Factors | 2 | 2018 | 631 | 0.160 |
Why?
|
| Drug Approval | 1 | 2017 | 9 | 0.160 |
Why?
|
| Aged | 4 | 2019 | 9487 | 0.160 |
Why?
|
| Double-Blind Method | 1 | 2019 | 501 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2018 | 134 | 0.160 |
Why?
|
| Penicillins | 1 | 2017 | 8 | 0.160 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2018 | 40 | 0.160 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 7 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 44 | 0.160 |
Why?
|
| Treponema pallidum | 1 | 2017 | 7 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 77 | 0.160 |
Why?
|
| Developing Countries | 1 | 2017 | 43 | 0.150 |
Why?
|
| Foot | 1 | 2017 | 40 | 0.150 |
Why?
|
| Age Factors | 2 | 2018 | 1108 | 0.150 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2017 | 7 | 0.150 |
Why?
|
| Drug Discovery | 1 | 2017 | 30 | 0.150 |
Why?
|
| Southeastern United States | 1 | 2017 | 71 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2018 | 138 | 0.150 |
Why?
|
| Microscopy | 1 | 2017 | 27 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2016 | 78 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 42 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2017 | 159 | 0.140 |
Why?
|
| Young Adult | 3 | 2018 | 2402 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 206 | 0.140 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2016 | 2 | 0.140 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2016 | 5 | 0.140 |
Why?
|
| Disease Progression | 1 | 2018 | 572 | 0.140 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 7 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 96 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 298 | 0.140 |
Why?
|
| Animals | 2 | 2018 | 7297 | 0.140 |
Why?
|
| Mycophenolic Acid | 2 | 2017 | 28 | 0.130 |
Why?
|
| Prevalence | 1 | 2017 | 896 | 0.130 |
Why?
|
| Panniculitis, Lupus Erythematosus | 1 | 2014 | 5 | 0.130 |
Why?
|
| Psychometrics | 1 | 2015 | 129 | 0.120 |
Why?
|
| Scurvy | 1 | 2013 | 3 | 0.120 |
Why?
|
| Methotrexate | 2 | 2017 | 60 | 0.120 |
Why?
|
| Incidence | 1 | 2017 | 1119 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2017 | 1167 | 0.110 |
Why?
|
| North Carolina | 1 | 2016 | 1423 | 0.110 |
Why?
|
| Immunosuppression | 1 | 2012 | 80 | 0.100 |
Why?
|
| Parkinson Disease | 1 | 2012 | 68 | 0.100 |
Why?
|
| Muscle Strength | 1 | 2012 | 139 | 0.100 |
Why?
|
| Remission Induction | 1 | 2010 | 78 | 0.090 |
Why?
|
| Prednisone | 1 | 2010 | 43 | 0.090 |
Why?
|
| United States | 1 | 2017 | 3630 | 0.090 |
Why?
|
| Nonprescription Drugs | 1 | 2008 | 18 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 3717 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 525 | 0.080 |
Why?
|
| Calcitriol | 1 | 2008 | 23 | 0.080 |
Why?
|
| Barium | 1 | 2008 | 4 | 0.080 |
Why?
|
| Viscosity | 1 | 2008 | 21 | 0.080 |
Why?
|
| Rheology | 1 | 2008 | 28 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 148 | 0.080 |
Why?
|
| Biopsy | 2 | 2018 | 241 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2019 | 3099 | 0.050 |
Why?
|
| Streptococcus | 1 | 2019 | 7 | 0.050 |
Why?
|
| Pemphigoid, Bullous | 1 | 2019 | 6 | 0.050 |
Why?
|
| Thigh | 1 | 2019 | 39 | 0.040 |
Why?
|
| Fever | 1 | 2019 | 56 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 33 | 0.040 |
Why?
|
| Perception | 1 | 2018 | 92 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2018 | 142 | 0.040 |
Why?
|
| Chikungunya virus | 1 | 2017 | 1 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2018 | 108 | 0.040 |
Why?
|
| Hypopigmentation | 1 | 2017 | 7 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 144 | 0.040 |
Why?
|
| Skin Pigmentation | 1 | 2017 | 23 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 162 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2017 | 52 | 0.040 |
Why?
|
| Neurofibromatosis 2 | 1 | 2016 | 5 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 464 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2017 | 149 | 0.030 |
Why?
|
| Neurofibromatosis 1 | 1 | 2016 | 9 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 430 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2018 | 259 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2017 | 93 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 815 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 518 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 143 | 0.030 |
Why?
|